<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Alzamend Neuro Inc — News on 6ix</title>
    <link>https://6ix.com/company/alzamend-neuro-inc</link>
    <description>Latest news and press releases for Alzamend Neuro Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 07 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/alzamend-neuro-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835459578dffbe2df0e29cf.webp</url>
      <title>Alzamend Neuro Inc</title>
      <link>https://6ix.com/company/alzamend-neuro-inc</link>
    </image>
    <item>
      <title>Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 &quot;Lithium in Brain&quot; Study in a Trial Conducted at Massachusetts General Hospital</title>
      <link>https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-reports-encouraging-pharmacodynamic-data-from-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-in-a-trial-conducted-at-massachusetts-general-hospital</link>
      <guid isPermaLink="true">https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-reports-encouraging-pharmacodynamic-data-from-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-in-a-trial-conducted-at-massachusetts-general-hospital</guid>
      <pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
      <description>Potentially Distinct Brain Profile: Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry</description>
    </item>
    <item>
      <title>Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 &quot;Lithium in Brain&quot; Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions</title>
      <link>https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-reports-positive-topline-data-from-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-al001-achieves-bioequivalence-and-demonstrates-superior-brain-delivery-across-all-measured-brain-regions</link>
      <guid isPermaLink="true">https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-reports-positive-topline-data-from-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-al001-achieves-bioequivalence-and-demonstrates-superior-brain-delivery-across-all-measured-brain-regions</guid>
      <pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
      <description>Bioequivalence Confirmed: AL001 delivered 101% of total lithium blood exposure and 97% of peak lithium levels vs. standard lithium carbonateSuperior Brain</description>
    </item>
    <item>
      <title>Alzamend Neuro Initiates Phase II Clinical Trial of AL001 &quot;Lithium in Brain&quot; Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital</title>
      <link>https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-initiates-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-in-patients-with-bipolar-disorder-in-collaboration-with-massachusetts-general-hospital</link>
      <guid isPermaLink="true">https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-initiates-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-in-patients-with-bipolar-disorder-in-collaboration-with-massachusetts-general-hospital</guid>
      <pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
      <description>Head-to-head studies of AL001 versus marketed lithium carbonate will compare lithium blood and brain/brain-structure pharmacokinetics in bipolar disorder type</description>
    </item>
    <item>
      <title>Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 &quot;Lithium in Brain&quot; Study Conducted at Massachusetts General Hospital</title>
      <link>https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-completion-clinical-130000595</link>
      <guid isPermaLink="true">https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-completion-clinical-130000595</guid>
      <pubDate>Wed, 19 Nov 2025 13:00:00 GMT</pubDate>
      <description>Alzamend Neuro, Inc. (Nasdaq: ALZN) (&quot;Alzamend&quot;), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer&apos;s disease (&quot;Alzheimer&apos;s&quot;), bipolar disorder (&quot;BD&quot;), major depressive disorder (&quot;MDD&quot;) and post-traumatic stress disorder (&quot;PTSD&quot;), today announced completion of the clinical portion of its first Phase II clinical study of AL001, in healthy human subjects.</description>
    </item>
    <item>
      <title>Alzamend Neuro to Present at the 2025 Military Health System Research Symposium</title>
      <link>https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-present-2025-military-120000535</link>
      <guid isPermaLink="true">https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-present-2025-military-120000535</guid>
      <pubDate>Mon, 28 Jul 2025 12:00:00 GMT</pubDate>
      <description>Session Topic is the Innovation and Current Directions in Military Suicide Prevention, Research, and ProgramsPresentation Title is Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD Subjects Between AL001 and Lithium Carbonate ATLANTA, July 28, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”),</description>
    </item>
    <item>
      <title>Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs</title>
      <link>https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-reports-annual-2025-120000525</link>
      <guid isPermaLink="true">https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-reports-annual-2025-120000525</guid>
      <pubDate>Wed, 23 Jul 2025 12:00:00 GMT</pubDate>
      <description>During the year ended April 30, 2025, net cash provided by financing activities was $10.4 millionStockholder equity of $4.0 million at April 30, 2025, including $3.9 million of cashIn May 2025, Alzamend dosed the first patient for the healthy human patients for the AL001 “Lithium in Brain” Studies at Massachusetts General HospitalIn June 2025, Alzamend completed the final closing of its $5 million private placement months ahead of schedule ATLANTA, July 23, 2025 (GLOBE NEWSWIRE) -- Alzamend Neur</description>
    </item>
    <item>
      <title>Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule</title>
      <link>https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-final-closing-120000979</link>
      <guid isPermaLink="true">https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-final-closing-120000979</guid>
      <pubDate>Mon, 16 Jun 2025 12:00:00 GMT</pubDate>
      <description>Capital Raised to Support Five Clinical TrialsATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it has completed the final closing of its $5 million private placement. As previously reported, on</description>
    </item>
    <item>
      <title>Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital</title>
      <link>https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-dosing-first-120000038</link>
      <guid isPermaLink="true">https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-dosing-first-120000038</guid>
      <pubDate>Thu, 29 May 2025 12:00:00 GMT</pubDate>
      <description>Massachusetts General Hospital Main Entrance Massachusetts General Hospital Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’</description>
    </item>
    <item>
      <title>Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital</title>
      <link>https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-enrolls-first-patient-120000739</link>
      <guid isPermaLink="true">https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-enrolls-first-patient-120000739</guid>
      <pubDate>Mon, 19 May 2025 12:00:00 GMT</pubDate>
      <description>Massachusetts General Hospital Main Entrance Massachusetts General Hospital Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 19, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’</description>
    </item>
    <item>
      <title>Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital</title>
      <link>https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-initiates-first-phase-120000772</link>
      <guid isPermaLink="true">https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-initiates-first-phase-120000772</guid>
      <pubDate>Tue, 13 May 2025 12:00:00 GMT</pubDate>
      <description>Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 13, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorde</description>
    </item>
    <item>
      <title>Alzamend Neuro Announces Reverse Stock Split</title>
      <link>https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-reverse-stock-120000921</link>
      <guid isPermaLink="true">https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-reverse-stock-120000921</guid>
      <pubDate>Thu, 08 May 2025 12:00:00 GMT</pubDate>
      <description>ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that Alzamend’s board of directors approved a one-for-nine reverse stock split of Alzamend’s common stock (“Common Stock”) that will</description>
    </item>
    <item>
      <title>Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital</title>
      <link>https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-partners-qmenta-advance-120000493</link>
      <guid isPermaLink="true">https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-partners-qmenta-advance-120000493</guid>
      <pubDate>Wed, 07 May 2025 12:00:00 GMT</pubDate>
      <description>Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 07, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stre</description>
    </item>
    <item>
      <title>Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital</title>
      <link>https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-initiation-date-120000603</link>
      <guid isPermaLink="true">https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-initiation-date-120000603</guid>
      <pubDate>Tue, 25 Mar 2025 12:00:00 GMT</pubDate>
      <description>Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in Alzheimer’s subjectsATLANTA, March 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic</description>
    </item>
    <item>
      <title>Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital</title>
      <link>https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-initiation-date-120000924</link>
      <guid isPermaLink="true">https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-initiation-date-120000924</guid>
      <pubDate>Tue, 18 Mar 2025 12:00:00 GMT</pubDate>
      <description>Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in MDD subjects ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress</description>
    </item>
    <item>
      <title>Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital</title>
      <link>https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-initiation-date-120000402</link>
      <guid isPermaLink="true">https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-initiation-date-120000402</guid>
      <pubDate>Tue, 11 Mar 2025 12:00:00 GMT</pubDate>
      <description>Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in PTSD subjects Approx 1 in 13 People in the US PTSD Approximately 1 in 13 people in the US will develop PTSD in their lifetime. All rights reserved; proprietary content owned by Alzamend Neuro, Inc. 9 Million Americans Live w PTSD It is estimated that 9 Million Americans are currently living with PTSD while women are 2 times mor</description>
    </item>
    <item>
      <title>Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital</title>
      <link>https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-initiation-date-131000691</link>
      <guid isPermaLink="true">https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-initiation-date-131000691</guid>
      <pubDate>Tue, 04 Mar 2025 13:10:00 GMT</pubDate>
      <description>Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in Bipolar Disorder subjects Bipolar Disorder Statement Over 7 Million Americans are projected to be living with Bipolar Disorder.Bipolar disorder (BD) is a medical condition that causes dramatic shifts in a person&apos;s mood, energy, and ability to think clearly.@2025 all rights reserved, property of Alzamend Neuro, Inc. Bipolar Diso</description>
    </item>
    <item>
      <title>Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital</title>
      <link>https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-initiation-date-130000406</link>
      <guid isPermaLink="true">https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-initiation-date-130000406</guid>
      <pubDate>Tue, 25 Feb 2025 13:00:00 GMT</pubDate>
      <description>Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy human subjectsATLANTA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumati</description>
    </item>
    <item>
      <title>Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital</title>
      <link>https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-completion-novel-130000132</link>
      <guid isPermaLink="true">https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-completion-novel-130000132</guid>
      <pubDate>Wed, 19 Feb 2025 13:00:00 GMT</pubDate>
      <description>ATLANTA, February 19, 2025--Alzamend Neuro Announces Completion of Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials</description>
    </item>
    <item>
      <title>Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs</title>
      <link>https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-reports-second-quarter-2025-financial-results-and-provides-update-on-clinical-programs</link>
      <guid isPermaLink="true">https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-reports-second-quarter-2025-financial-results-and-provides-update-on-clinical-programs</guid>
      <pubDate>Thu, 12 Dec 2024 05:00:00 GMT</pubDate>
      <description>During the six months ended October 31, 2024, net cash provided by financing activities was $8.3 million Stockholder equity of $3.8 million at October 31,</description>
    </item>
    <item>
      <title>Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice</title>
      <link>https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-full-data-set-from-its-nonclinical-study-comparing-brain-and-plasma-lithium-exposures-between-al001-and-lithium-carbonate-in-alzheimers-transgenic-mice</link>
      <guid isPermaLink="true">https://6ix.com/company/alzamend-neuro-inc/news/alzamend-neuro-announces-full-data-set-from-its-nonclinical-study-comparing-brain-and-plasma-lithium-exposures-between-al001-and-lithium-carbonate-in-alzheimers-transgenic-mice</guid>
      <pubDate>Tue, 19 Nov 2024 05:00:00 GMT</pubDate>
      <description>Alzamend is developing AL001, a lithium product designed for enhanced safety and efficacy compared to currently available FDA-approved and marketed lithium</description>
    </item>
  </channel>
</rss>